ACERAGEN INC (ACGN) Stock Price, Forecast & Analysis
USA - NASDAQ:ACGN - US00445F1093 - Common Stock
ACGN Key Statistics, Chart & Performance
The current stock price of ACGN is 0.38 USD. In the past month the price decreased by -48.99%.
ACGN Latest News, Press Relases and Analysis
ACGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About ACGN
Company Profile
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Exton, Pennsylvania and currently employs 26 full-time employees. The firm is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
Company Info
ACERAGEN INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA US
Employees: 26
Phone: 14843481600.0
ACERAGEN INC / ACGN FAQ
What does ACERAGEN INC do?
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Exton, Pennsylvania and currently employs 26 full-time employees. The firm is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
Can you provide the latest stock price for ACERAGEN INC?
The current stock price of ACGN is 0.38 USD. The price decreased by -13.83% in the last trading session.
Does ACGN stock pay dividends?
ACGN does not pay a dividend.
What is the ChartMill rating of ACERAGEN INC stock?
ACGN has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
Can you provide the number of employees for ACERAGEN INC?
ACERAGEN INC (ACGN) currently has 26 employees.
What is the market capitalization of ACGN stock?
ACERAGEN INC (ACGN) has a market capitalization of 3.20M USD. This makes ACGN a Nano Cap stock.
When does ACERAGEN INC (ACGN) report earnings?
ACERAGEN INC (ACGN) will report earnings on 2023-11-13, after the market close.
ACGN Technical Analysis
ACGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACGN Forecast & Estimates
7 analysts have analysed ACGN and the average price target is 17.34 USD. This implies a price increase of 4463.16% is expected in the next year compared to the current price of 0.38.